[go: up one dir, main page]

EP2819658A2 - Formulation pharmaceutique contenant de flupirtine - Google Patents

Formulation pharmaceutique contenant de flupirtine

Info

Publication number
EP2819658A2
EP2819658A2 EP13708685.6A EP13708685A EP2819658A2 EP 2819658 A2 EP2819658 A2 EP 2819658A2 EP 13708685 A EP13708685 A EP 13708685A EP 2819658 A2 EP2819658 A2 EP 2819658A2
Authority
EP
European Patent Office
Prior art keywords
microtablets
preparation according
release
active ingredient
medicament preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13708685.6A
Other languages
German (de)
English (en)
Inventor
Katrin Moschner
Torsten Hoffmann
Mario Weingart
Annegret Hildebrand-Cyrener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Publication of EP2819658A2 publication Critical patent/EP2819658A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the invention relates to controlled-release pharmaceutical preparations in the form of microtablets containing flupirtine or one of its physiologically acceptable salts as active ingredient, and to processes for their preparation.
  • Flupirtine (Katadolon TM) is a centrally acting, non-opiate analgesic.
  • CONFIRMATION COPY Flupirtin is usually administered orally, rectally or parenterally.
  • the daily dosages are usually 300-600 mg when given orally. To ensure optimal pain management, it is desirable to release the drug evenly over an extended period of time to reduce daily doses.
  • multiparticulate dosage forms consist of sustained-release film-coated individual particles, granules or pellets which have been compressed into tablets. If these film-coated particles, granules or pellets are compressed into a tablet with or without further excipients, it is possible that the film will be damaged by the deformation.
  • the present invention is therefore based on the object, a flupirtine containing multiple unit - drug form with sustained release drug
  • microtablets based on granules obtained by granulation, preferably dry granulation, which has a high proportion of active ingredient. At least a portion of the microtablets are subsequently coated with a retarding film and optionally filled into a capsule, a sachet, a stick, a bag or a single-dose dispenser.
  • the microtablets have a smaller volume with the same amount of active ingredient, and thus the compliance is significantly increased. In addition, they are variable in dosage and therefore as well
  • Micro-tablets can be pressed, even if the active ingredient content is very high and is dispensed with the conventionally necessary excipients. Thus, one is
  • the microtablets thus obtained have a more uniform geometry, more uniform weight and lower porosity (defined surface area) in comparison to granules, active ingredient particles and pellets.
  • a reproducible Befilmungsprozeß is possible.
  • Granules or pellets, on the other hand, are often uneven in shape and have a rough and uneven surface, which makes subsequent filming difficult.
  • microtablets In addition, almost complete processing into microtablets is possible, during which, in the case of conventional pelletizing of pellets and granules, grain size selection (screening) has to be carried out. Otherwise, the fluctuations in the surface to be coated are too great, with the same quantity application, release fluctuations are the result. Due to the standardized surface of the microtablets, the amount of film application is uniformly dosed, resulting in a more uniform layer thickness of the film, the drug release is reproducible.
  • the retarding coating is hardly damaged during the dosing process. This ensures a more uniform drug release, drug release tips are avoided (dose dumping).
  • a big advantage over multiple unit tablets is that drug release of the microtablets is independent of the disintegration time of a tablet in the stomach into the single retard particles.
  • the food influences are lower, i. the rate of gastric and pyrolus passage of the microtablets for
  • Absorption site (small intestine) is independent of the filling state of the stomach.
  • microtablets to be produced allow a large variability in the design of the single-dose unit, eg the combination of microtablets with different drug release profiles (fast and delayed release) or the combination of microtablets with various, even mutually chemically incompatible, active ingredients in a capsule, a sachet, a stick, a bag or a Einzeldosierspender is possible.
  • microtablets have the advantage of being at
  • Dysphagia can be better applied than large tablets.
  • the filling of the micro-tablets from a capsule, a sachet, a stick, a bag or a single dosing dispenser and the intake with food is easily possible, the administration with a nasogastric tube is possible.
  • the sustained release effect is not affected.
  • the preparation of the dosage forms according to the invention is carried out by the active ingredient flupirtine or one of its pharmaceutically acceptable salts, preferably
  • Dry granulator (roller compactor) is granulated. The entire granulate is processed further.
  • the resulting granules are optionally mixed with other excipients, preferably with magnesium stearate, highly disperse silica, cross-carmellose sodium and optionally microcrystalline cellulose and mixed in a container mixer.
  • This tablettable mixture is added to a rotary tablet press
  • Microtablets in a filming apparatus are coated with an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), talc, yellow iron oxide, polysorbate 80 and hydroxypropylmethylcellulose.
  • the required drug release profile is achieved by mixing the appropriate proportions of sustained-release and immediate-release micro-tablets.
  • the single dose of micro-tablets is filled into a capsule, a sachet, a stick, a bag or a single-dose dispenser.
  • the proportion of excipients in the microtablets is between 0.1 and 25% (w / w), preferably between 1 and 20% (w / w), more preferably between 3.5 and 5.5% (w / w) or between 11 and 16% (w / w).
  • the sustained-release coating is between 0.01 and 25% (w / w), between 1 and 15% (w / w), preferably between 4 and 9% (w / w), particularly preferably between 5.5% (w / w ) and 7.5% (w / w) of the delayed release microtablets.
  • the sustained release coating is between 1 and 25% (w / w), between 5 and 10% (w / w), between 10 and 15% (w / w), between 15 and 20% (w / w), between 20 and 25% (w / w), between 5 and 6% (w / w), between 6 and 7% (w / w), between 7 and 8% (w / w), between 8 and 9% ( w / w), between 9 and 10% (w / w), between 10 and 11% (w / w), between 11 and 12% (w / w), between 12 and 13% (w / w), between 13 and 14% (w / w), between 14 and 15% (w / w), between 15 and 16% (w / w), between 16 and 17% (w / w), between 17 and 18% (w / w), between 18 and 19% (w / w), between 19 and 20% (w / w), between 20 and 21% (w / w),
  • the sustained-release coating achieves a uniform in vitro release of active ingredient from the dosage form according to the invention of between 30 and 80% within 4 hours.
  • a uniform in vitro release of active ingredient from the dosage form according to the invention of between 30 and 80% within 4 hours.
  • the proportion of immediate-release flupirtine microtablets at which the drug release rate is at least 80% in 45 minutes one can vary the proportion of immediate-release flupirtine microtablets at which the drug release rate is at least 80% in 45 minutes.
  • Release can be achieved within 15 minutes between 15 and 35%, or in another embodiment within 4 hours between 50 and 75%. After a period of 10 hours, the release of the active ingredient is at least 75% of the flupirtin or its physiologically acceptable salts. Thus, even drug levels are achieved in vivo.
  • the in vitro release rate of the active substance from the pharmaceutical preparation is carried out at 100 rpm in a buffer according to Ph. Eur. At pH 6.8 at 37 ° C. using the Ph. Eur. Paddle method Measurement determined with a UV spectrophotometer. Further constituents may be all auxiliaries known to the person skilled in the art.
  • Binders preferably cellulose derivatives such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose and salts thereof, alginic acid and its salts, propylene glycol alginate, xanthans, starch, carboxymethyl starch, can be used. It can also simultaneously
  • binders for example different cellulose derivatives
  • flow control agents may preferably silicas, silified
  • microcrystalline cellulose microcrystalline cellulose
  • the disintegrating agents used are preferably croscarmellose, starch, cellulose, pectins, alginates, carboxymethylcellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, ultraamylopectin.
  • Magnesium stearate, stearic acid, talc, calcium stearate, glyceryl behenate, glyceryl monostearate, glyceryl palmitostearate, sodium stearyl fumarate, polyethylene glycols are preferably used as molding / release agents.
  • Preferred fillers are starch (e.g., potato starch, corn starch, modified starch), cellulose (e.g., microcrystalline, silicified microcrystalline),
  • Preferred coatings for the retardation are:
  • Carboxymethyl cellulose polyvinyl acetate, methyl cellulose phthalate,
  • Methacrylic acid and methacrylic esters (Eudragit® L, Eudragit® S), copolymers of acrylic and methacrylic acid esters with a low content of
  • Trimethylammonium methacrylate (Eudragit® RL; Eudragt® RS), copolymer of acrylic acid, methacrylic acid and their esters (ratio of free carboxyl groups to ester groups eg 1: 1) (Eudragit® L30 D, Eudragit® L100), copolymers of ethyl acrylate and methyl methacrylate ( Eudragit® NE 30D, Eudragit NM 30 D), polyvinyl acetate dispersion (Kollicoat® SR 30D), methacrylic acid ethyl acrylate copolymer (Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P).
  • Preferred plasticizers are e.g. Dibutyl sebacate, citric and tartaric acid esters, glycerol and glycerol esters, phthalic acid esters.
  • Preferred release agents and pigments are talc, magnesium stearate, iron oxides, glycerol monostearate, calcium arachinate, glycerol palmitostearate, stearic acid and triglycerides.
  • the daily dosages are between 20 and 800 mg, between 50 and 600 mg, between 100 and 600 mg, preferably between 300 and 600 mg, more preferably 400 mg, and 200 to 300 mg in children.
  • a single dose is between 20 and 600 mg, preferably 400 mg or 75 mg in children.
  • compositions according to the invention are for example for
  • Impairment of the haemopoietic cell system against neurodegenerative diseases, against Creutzfeldt-Jacob disease, as
  • Antiphlogisticum or used as muscle relaxant are examples of Antiphlogisticum or used as muscle relaxant.
  • the medicament formulations according to the invention may be used in combination with other active substances, in particular from the group of opioids, such as, for example, sufentanil, remifentanil, fentanyl, alfentanil, buprenorphine, hydromorphone,
  • opioids such as, for example, sufentanil, remifentanil, fentanyl, alfentanil, buprenorphine, hydromorphone
  • Levomethadone oxycodone, diacetylmorphine, methadone, hydrocodone, morphine, piritramide, nalbuphine, pentazocine, codeine, dihydrocodeine, pethidine, tramadol, tilidine, naloxone, naltrexone, loperamide, apomorphine or their pharmaceutically acceptable salts.
  • a dosing unit is at all
  • Drug combinations any combination of fast-release and delayed-release micro-tablets possible.
  • the active ingredient flupirtine maleate is granulated in a dry granulator (roller compactor). The resulting entire granulate is processed further.
  • 0.96 kg of the granules thus obtained are admixed with 0.012 kg of magnesium stearate, 0.01 kg of fumed silica and 0.02 kg of cross-carmellose sodium and mixed in a container mixer.
  • This tablettable mixture is added to a rotary tablet press
  • Micro-tablets with a diameter of 2 mm are pressed.
  • Befilmungsapparatur (Trommelcoater, fluidized bed apparatus) with 58 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 17 g of talc, 1, 8 g of iron oxide yellow, 1, 7 g of polysorbate 80 and 1, 7 g of hydroxypropylmethylcellulose befilmt.
  • Example 3
  • the active ingredient flupirtine maleate is granulated in a dry granulator (roller compactor). The resulting entire granulate is processed further.
  • 0.87 kg of the granules thus obtained are mixed with 0.10 kg of microcrystalline cellulose, 0.012 kg of magnesium stearate, 0.01 kg of fumed silica and 0.01 kg of cross-carmellose sodium and mixed in a container mixer.
  • This tablettable mixture is added to a rotary tablet press
  • Micro-tablets with a diameter of 2 mm are pressed.
  • Befilmungsapparatur (Trommelcoater, fluidized bed apparatus) with 58 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 17 g of talc, 1, 8 g of iron oxide yellow, 1, 7 g of polysorbate 80 and 1, 7 g of hydroxypropylmethylcellulose befilmt.
  • the active ingredient tramadol hydrochloride is in a dry granulator
  • 0.96 kg of the granules thus obtained are admixed with 0.012 kg of magnesium stearate, 0.01 kg of fumed silica and 0.02 kg of cross-carmellose sodium and mixed in a container mixer.
  • This tablettable mixture is added to a rotary tablet press
  • Micro-tablets with a diameter of 2 mm are pressed.
  • Filming apparatus drum coater, fluidized bed apparatus
  • 58 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D)
  • 17 g of talc 17 g
  • 1, 7 g of polysorbate 80 1, 7 g of hydroxypropylmethylcellulose befilmt.
  • the required drug release profile is obtained by mixing or dosing the appropriate proportions of microtablets from Examples 1 and 2, 1 and 4, 1 and 9, 1 and 11, 1 and 13, 1 and 15, 2 and 3, 3 and 4, 3 and 10, 3 and 12, 3 and 14, 3 and 16 achieved.
  • the individual single dose of microtablets is filled into a capsule, a sachet, a stick, a bag or a single dosing dispenser.
  • the required drug release profile is achieved by mixing or dosing the appropriate proportions of microtablets from Examples 1 and 5, 1 and 6, 2 and 5 or 2 and 6.
  • the individual single dose of microtablets is filled into a capsule, a sachet, a stick, a bag or a single dosing dispenser.
  • Filming apparatus drum coater, fluidized bed apparatus
  • 116 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D)
  • 17 g of talc 17 g
  • 1, 8 g of iron oxide yellow 17 g
  • polysorbate 80 3.5 g
  • silica filmed 3.5 g
  • Filming apparatus drum coater, fluidized bed apparatus
  • 116 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D)
  • 17 g of talc 17 g
  • 1, 8 g of iron oxide yellow 17 g
  • polysorbate 80 3.5 g
  • silica filmed 3.5 g
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 1 in a
  • Filming apparatus drum coater, fluidized bed apparatus
  • 232 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D)
  • 1.8 g of iron oxide yellow 7 g of polysorbate 80
  • 20.9 g of silica film-coated 20.9 g
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 3 in one
  • Filming apparatus drum coater, fluidized bed apparatus
  • 232 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 1, 8 g of iron oxide yellow, 7 g of polysorbate 80 and 20.9 g of silica film-coated.
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 1 in one
  • Foilmungsapparatur (Trommelcoater, fluidized bed apparatus) with 348 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 1, 8 g of iron oxide yellow, 10.5 g of polysorbate 80 and 31, 3 g of silica filmed.
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 3 in one
  • Foilmungsapparatur (Trommelcoater, fluidized bed apparatus) with 348 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 1, 8 g of iron oxide yellow, 10.5 g of polysorbate 80 and 31, 3 g of silica filmed.
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 1 in one
  • Foilmungsapparatur drum coater, fluidized bed apparatus
  • 464 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 1, 8 g of iron oxide yellow, 14 g of polysorbate 80 and 41, 8 g of silica befilmt.
  • Modified drug-release microtablets containing flupirtine maleate 600 g of the microtablets are prepared as in Example 3 in one
  • Foilmungsapparatur drum coater, fluidized bed apparatus
  • 464 g of an aqueous suspension of polyacrylate dispersion 30% (Eudragit NM 30 D), 1, 8 g of iron oxide yellow, 14 g of polysorbate 80 and 41, 8 g of silica befilmt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques à libération contrôlée de principe actif se présentant sous forme de microcomprimés, contenant comme principe actif de la flupirtine ou un de ses sels physiologiquement acceptables, ainsi que des procédés de production de ces préparations.
EP13708685.6A 2012-03-02 2013-03-01 Formulation pharmaceutique contenant de flupirtine Withdrawn EP2819658A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012004065 2012-03-02
PCT/EP2013/000615 WO2013127539A2 (fr) 2012-03-02 2013-03-01 Formulations pharmaceutiques

Publications (1)

Publication Number Publication Date
EP2819658A2 true EP2819658A2 (fr) 2015-01-07

Family

ID=47845907

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13708685.6A Withdrawn EP2819658A2 (fr) 2012-03-02 2013-03-01 Formulation pharmaceutique contenant de flupirtine

Country Status (13)

Country Link
US (1) US20150072006A1 (fr)
EP (1) EP2819658A2 (fr)
JP (1) JP2015508789A (fr)
CN (1) CN104302277A (fr)
AU (1) AU2013225352A1 (fr)
BR (1) BR112014021433A2 (fr)
CA (1) CA2864876A1 (fr)
EA (1) EA201491477A1 (fr)
HK (1) HK1204945A1 (fr)
MX (1) MX2014010460A (fr)
NZ (1) NZ628867A (fr)
WO (1) WO2013127539A2 (fr)
ZA (1) ZA201406407B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2664693C1 (ru) * 2017-10-05 2018-08-21 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ предоперационной подготовки пациентов к офтальмологическим операциям

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
BR9916972B1 (pt) * 1999-01-29 2010-05-18 composições farmacêuticas de liberação retardada melhorada, bem como seu processo de produção.
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
NZ547926A (en) * 2003-12-16 2009-10-30 Cnsbio Pty Ltd Methods and compositions for the treatment of neuropathic pain
US7553858B2 (en) * 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
DE102005054610B4 (de) * 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
EP2032168A4 (fr) * 2006-06-02 2010-12-29 Ariad Pharma Inc Therapie combinee a base de capecitabine
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013127539A3 *

Also Published As

Publication number Publication date
AU2013225352A1 (en) 2014-09-18
ZA201406407B (en) 2016-01-27
MX2014010460A (es) 2014-10-13
JP2015508789A (ja) 2015-03-23
WO2013127539A2 (fr) 2013-09-06
WO2013127539A3 (fr) 2013-12-19
CN104302277A (zh) 2015-01-21
NZ628867A (en) 2016-03-31
US20150072006A1 (en) 2015-03-12
HK1204945A1 (en) 2015-12-11
BR112014021433A2 (pt) 2017-07-18
CA2864876A1 (fr) 2013-09-06
EA201491477A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
DE19901687B4 (de) Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
KR101476574B1 (ko) 서방성 하이드로코돈 제형
DE69429826T2 (de) Opioid-formulierungen zur schmerzbehandlung
JP6550157B2 (ja) Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
TWI483748B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
NO323574B1 (no) Multippelenhets doseringsmateriale for modifisert avgivelse
CN103002881B (zh) 载有活性剂的颗粒与额外活性剂的组合
CN103002882B (zh) 不含活性剂之颗粒及包含其之片剂的制备
WO2000078289A1 (fr) Comprime a couches multiples pour l'administration d'une combinaison fixe de tramadol et de diclofenac
JP2006516969A (ja) 徐放性製剤及びその製造方法
DE19901683B4 (de) Analgetikum mit kontrollierter Wirkstofffreisetzung
CA2911486C (fr) Formulation a liberation modifiee
WO2013127539A2 (fr) Formulations pharmaceutiques
CN110381926A (zh) 新型剂型
WO2020212956A1 (fr) Composition de bromure d'otilonium pour voie orale
WO2013053485A1 (fr) Formulations contenant de la quétiapine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141002

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170215